{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:29:50Z","timestamp":1768422590301,"version":"3.49.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases (US), Intramural Research Program","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Contract No. HHSN261200800001E"],"award-info":[{"award-number":["Contract No. HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166393","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T14:09:34Z","timestamp":1479218974000},"page":"e0166393","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)"],"prefix":"10.1371","volume":"11","author":[{"given":"Michelle C.","family":"Crank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor M. P.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Novik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Enama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia S.","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha C.","family":"Nason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Bailer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Nabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie E.","family":"Ledgerwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barney S.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"VRC012 Study Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"The New England journal of medicine"},{"issue":"14","key":"ref2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"AT Catanzaro","year":"2006","journal-title":"The Journal of infectious diseases"},{"issue":"20","key":"ref4","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.vaccine.2007.02.050","article-title":"Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine","volume":"25","author":"AT Catanzaro","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"e91366","DOI":"10.1371\/journal.pone.0091366","article-title":"Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)","volume":"9","author":"ME Enama","year":"2014","journal-title":"PloS one"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/509259","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine","volume":"194","author":"BS Graham","year":"2006","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"e9015","DOI":"10.1371\/journal.pone.0009015","article-title":"Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses","volume":"5","author":"RA Koup","year":"2010","journal-title":"PloS one"},{"issue":"32","key":"ref8","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"DH Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"K McCoy","year":"2007","journal-title":"Journal of virology"},{"issue":"9653","key":"ref10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"G Gray","year":"2010","journal-title":"Current opinion in HIV and AIDS"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"GE Gray","year":"2011","journal-title":"The Lancet infectious diseases"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"DH Barouch","year":"2004","journal-title":"Journal of immunology"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"P Abbink","year":"2007","journal-title":"Journal of virology"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"TC Mast","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","article-title":"Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer&apos;s construct, or gene inserts","volume":"5","author":"RL Sheets","year":"2008","journal-title":"Journal of immunotoxicology"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"JE Ledgerwood","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.urology.2005.04.041","article-title":"Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants","volume":"66","author":"BS Malaeb","year":"2005","journal-title":"Urology"},{"issue":"9977","key":"ref20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"H Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"ref21","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine\u2014Preliminary Report","author":"JE Ledgerwood","year":"2014","journal-title":"The New England journal of medicine"},{"key":"ref22","unstructured":"Subcommittee AVR. AVRS Meeting Archive 2005 [updated 6\/27\/2011; cited 2014 3\/23]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.niaid.nih.gov\/topics\/HIVAIDS\/Research\/vaccines\/advisory\/avrs\/AVRSarchive\/Pages\/avrwgAug05.aspx\" xlink:type=\"simple\">http:\/\/www.niaid.nih.gov\/topics\/HIVAIDS\/Research\/vaccines\/advisory\/avrs\/AVRSarchive\/Pages\/avrwgAug05.aspx<\/ext-link>."},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.1000461","article-title":"Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals","volume":"6","author":"JD Fuchs","year":"2015","journal-title":"J AIDS Clin Res"},{"key":"ref24","article-title":"Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083)","author":"SR Walsh","year":"2015","journal-title":"The Journal of infectious diseases"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"e13579","DOI":"10.1371\/journal.pone.0013579","article-title":"Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054)","volume":"5","author":"L Peiperl","year":"2010","journal-title":"PloS one"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/JVI.76.11.5357-5368.2002","article-title":"Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization","volume":"76","author":"BK Chakrabarti","year":"2002","journal-title":"Journal of virology"},{"key":"ref27","unstructured":"Enama ME NL, Hendel CS, Sheets R, Ledgerwood JE, Graham BS., editor Induction of False-Positive PTT Elevations by Investigational Adenoviral Vector Vaccines. 14th Annual Conference on Vaccine Research; 2011 May 16\u201318, 2011; Baltimore, Maryland, U. S. A. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nfid.org\/professional-education\/archives\/acvr\/\" xlink:type=\"simple\">http:\/\/www.nfid.org\/professional-education\/archives\/acvr\/<\/ext-link>: National Foundation for Infectious Diseases; 2011."},{"key":"ref28","unstructured":"Graham BSL, J.E.; Novik, L.; Enama, M.E.; Hendel, C.S.; Nason, M.C.; Koup, R.A.; Mascola, J.R.; Nabel, G.J., editor Safety and immunogenicty of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC012) AIDS Vaccine 2010; 2010 October 15, 2010; Atlanta, Georgia, U. S. A. AIDS Research and Human Retroviruses2010."},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/nm.3413","article-title":"Another HIV vaccine failure: where to next?","volume":"19","author":"A McMichael","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1586\/erv.10.106","article-title":"Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1","volume":"9","author":"RM Paris","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"7383","key":"ref31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature10766","article-title":"Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys","volume":"482","author":"DH Barouch","year":"2012","journal-title":"Nature"},{"key":"ref32","article-title":"Translating the immunogenicity of prime-boost immunisation with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","author":"D Kimani","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"e74831","DOI":"10.1371\/journal.pone.0074831","article-title":"Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV\/AIDS vaccine candidate NYVAC-C","volume":"8","author":"B Perdiguero","year":"2013","journal-title":"PloS one"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"e48524","DOI":"10.1371\/journal.pone.0048524","article-title":"Deletion of the viral anti-apoptotic gene F1L in the HIV\/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens","volume":"7","author":"B Perdiguero","year":"2012","journal-title":"PloS one"},{"issue":"10","key":"ref35","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.03574-13","article-title":"Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses","volume":"88","author":"AM Chmielewska","year":"2014","journal-title":"Journal of virology"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1172\/JCI75894","article-title":"HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial","volume":"124","author":"PA Bart","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08830185.2013.823420","article-title":"Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection","volume":"33","author":"RF Chen","year":"2014","journal-title":"International reviews of immunology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fmicb.2013.00174","article-title":"Animal models for human herpesvirus 6 infection","volume":"4","author":"JM Reynaud","year":"2013","journal-title":"Frontiers in microbiology"},{"key":"ref39","first-page":"111","article-title":"Current animal models: transgenic animal models for the study of measles pathogenesis","volume":"330","author":"CI Sellin","year":"2009","journal-title":"Current topics in microbiology and immunology"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.179.3.1721","article-title":"Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses","volume":"179","author":"K Lore","year":"2007","journal-title":"Journal of immunology"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.4049\/jimmunol.1103717","article-title":"Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity","volume":"188","author":"MJ Johnson","year":"2012","journal-title":"Journal of immunology"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"KM Quinn","year":"2013","journal-title":"Journal of immunology"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"KM Quinn","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"DH Barouch","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"e41936","DOI":"10.1371\/journal.pone.0041936","article-title":"A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"MC Keefer","year":"2012","journal-title":"PloS one"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"e90378","DOI":"10.1371\/journal.pone.0090378","article-title":"Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"9","author":"J Kopycinski","year":"2014","journal-title":"PloS one"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"e0125954","DOI":"10.1371\/journal.pone.0125954","article-title":"A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults","volume":"10","author":"G Omosa-Manyonyi","year":"2015","journal-title":"PloS one"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.4161\/hv.26038","article-title":"Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults","volume":"9","author":"CB Creech","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"A Ouedraogo","year":"2013","journal-title":"PloS one"},{"issue":"15","key":"ref50","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts &gt;350 cells\/mm(3)","volume":"33","author":"GJ Churchyard","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.200910-1484OC","article-title":"The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults","volume":"181","author":"B Abel","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref52","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.vaccine.2012.01.048","article-title":"A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity","volume":"30","author":"DF Hoft","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"LR Baden","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"DH Barouch","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/jiu485","article-title":"Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans","volume":"211","author":"LR Baden","year":"2015","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial","volume":"164","author":"LR Baden","year":"2016","journal-title":"Ann Intern Med"},{"issue":"7","key":"ref57","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiu217","article-title":"First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)","volume":"210","author":"LR Baden","year":"2014","journal-title":"The Journal of infectious diseases"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"N Borthwick","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"GA O'Hara","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"115","key":"ref60","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"E Barnes","year":"2012","journal-title":"Sci Transl Med"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates","volume":"22","author":"S Capone","year":"2014","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s003450050181","article-title":"Osteocalcin-directed gene therapy for prostate-cancer bone metastasis","volume":"18","author":"KS Koeneman","year":"2000","journal-title":"World journal of urology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T02:06:29Z","timestamp":1540260389000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166393"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166393","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}